Bioidentical hormone replacement therapy (BHRT) uses molecules molecularly identical to those your body produces — estradiol, progesterone, testosterone. Traditional HRT typically uses synthetic or animal-derived analogs — conjugated equine estrogens, medroxyprogesterone acetate (Provera), synthetic androgens. The molecules differ in receptor binding, metabolism, clearance, and side-effect profile. Most modern hormone protocols use bioidentical molecules for these reasons; traditional preparations remain appropriate in specific clinical contexts.
"BHRT" and "traditional HRT" describe different molecules used to accomplish the same general goal: restoring hormone signaling in patients who have insufficient endogenous hormone production. The category names are not interchangeable, and the molecular differences produce real clinical differences that show up in side-effect profile, lab response, and long-term safety data.
A bioidentical hormone is a molecule with the exact chemical structure of a hormone produced by the human body. Bioidentical estradiol, for example, is the same 18-carbon steroid molecule as the estradiol secreted by human ovaries. When introduced into the body, it binds estrogen receptors identically, is metabolized identically, and is cleared through the same enzyme pathways as endogenous estradiol.
A synthetic or non-human hormone analog is a different molecule designed to bind the same receptors. Conjugated equine estrogens (the active ingredient in Premarin) are a mixture of estrogen molecules derived from pregnant mare urine, including estrogens that the human body does not produce. Medroxyprogesterone acetate (the active ingredient in Provera) is a synthetic progestin — it binds the progesterone receptor but is not the same molecule as endogenous progesterone. Synthetic androgens like methyltestosterone are oral-bioavailable modifications of testosterone that the liver processes differently from native testosterone.
Receptor binding, downstream signaling, and metabolism are not identical between bioidentical and synthetic molecules. This produces concrete clinical differences:
| Domain | Bioidentical (BHRT) | Synthetic/Equine (Traditional) |
|---|---|---|
| Estrogen molecule | Estradiol (E2), estriol (E3) | Conjugated equine estrogens (mix of human and equine estrogens) |
| Progesterone molecule | Micronized progesterone (USP, oral or topical) | Medroxyprogesterone acetate, norethindrone, drospirenone |
| Sleep and mood | Oral micronized progesterone is sedating and pro-GABAergic; many women sleep better on it | Synthetic progestins are not GABAergic; mood/sleep effects differ |
| Breast tissue signaling | Endogenous-pattern signaling | Synthetic progestin signaling differs; some evidence suggests different breast tissue effects |
| Endometrial protection | Provided by micronized progesterone in adequate dose | Provided by synthetic progestins; protection is real, side-effect profile differs |
| Route options | Oral, transdermal cream, transdermal patch, vaginal, subcutaneous pellet, sublingual | Primarily oral and patch |
| Lab measurement | Serum estradiol and progesterone reflect circulating bioidentical hormone | Conjugated equine estrogens do not measure cleanly on standard estradiol assays |
Much of the lingering hesitancy about hormone therapy traces to the 2002 Women's Health Initiative trial, which reported increased risk of breast cancer, cardiovascular events, and stroke in women on combined conjugated equine estrogen + medroxyprogesterone acetate (Premarin + Provera). That study shaped a generation of clinical practice and patient perception.
What the study did not establish: that all hormone therapy carries those risks. WHI specifically tested conjugated equine estrogens combined with medroxyprogesterone acetate in older postmenopausal women (mean age 63 at enrollment) with oral administration. Subsequent analyses have shown that the risk profile is different for transdermal vs oral routes, for bioidentical vs synthetic progestins, and for women started in the perimenopausal window vs decades after menopause. Modern guidelines (NAMS 2022 Position Statement) reflect this more nuanced picture.
This does not mean WHI's findings are obsolete — the risks identified in that study are real for the population and regimen tested. It means the conclusion "hormone therapy is dangerous" is an overgeneralization that doesn't accurately describe modern, well-monitored, bioidentical protocols.
BHRT is not always the right answer. Some patients respond best to specific traditional preparations for specific reasons. Birth control pills (synthetic estrogens and progestins) remain appropriate when contraception is part of the goal. Some women on long-standing conjugated equine estrogen regimens that are working well don't benefit from switching. Clinical context drives the choice, not a blanket preference for one category.
At THE WELLNESS CO. we default to bioidentical molecules for our hormone protocols because the receptor identity, transdermal route options, and side-effect profile align with how we want to monitor and adjust. But our role is to match the molecule, dose, and route to the patient — not to evangelize one category over another.
The CLARITY methodology is biomarker-driven, route-flexible, and individually calibrated. We track serum estradiol, free and total testosterone, SHBG, progesterone, and the clinical-context biomarkers (hematocrit, lipids, thyroid, metabolic) on a structured schedule. The molecules we use are bioidentical because that's what allows the lab data to reflect what's circulating and what allows us to titrate to a target rather than to a population norm. See the methodology in full.
For our specific BHRT and TRT protocols, see the BHRT page and the TRT page. For more on hormone-related conditions, see menopause and low testosterone.
Upload it. Our clinical team reads it through the CLARITY framework — free.
Get Your Free Lab Review →One consultation. Your biomarkers map the protocol.
Book Your Consultation